Effect of Abhraloha tablets in anaemia

Evaluation of efficacy and tolerability of Abhraloha tablets in iron deficiency anaemia â?? Phase IV study - AIDA

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2020/12/029883

Enrollment

120

Registered

2020-12-17

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D509- Iron deficiency anemia, unspecified

Interventions

Intervention1: Tab. Abhraloha: It is an proprietary ayurvedic formulation used in the dose of 2 tab twice in a day in IDA.Treatment duration is 2 months. Control Intervention1: Not applicable: Not app

Eligibility

Inclusion criteria

Inclusion criteria: Patients ready to give informed consent. Patients of either gender between 18 to 50 years Patients fulfilling diagnostic criteria

Exclusion criteria

Exclusion criteria: Anemia other than Iron deficiency. K/C/O Thalassemia, Myelodysplastic syndrome, Co-exsisting infection, Inflammation etc K/C/O serious Hepatic, Renal, Pulmonary disease, malignancy etc. Patients receiving treatment with any other hematinic drug or multivitamins will be excluded from study. Pregnant and Lactating Woman Past history of hypersensitivity to any of the ingredients of study medicine.

Design outcomes

Primary

Measure	Time frame
Mean change in Hb %Timepoint: 2 months	—

Secondary

Measure	Time frame
Safety assessed by incidence of adverse events and any abnormal laboratory parameters during the study duration.Timepoint: 2 months	—

Countries

India

Contacts

Public ContactDr Nisha Jagannath Munishwar

Parul Institute of Ayurved

manu.r260022@paruluniversity.ac.in9481328930

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026